The vaginal ring conferred a 90% higher risk of venous thrombosis than did combined oral contraceptives containing levonorgestrel, bringing the risk to the same level as that of combined oral contraceptives with third and fourth generation progestogens.
Past News ReleasesRSS
New York, New York (PRWEB) May 14, 2012
Chaffin Luhana LLP, a national plaintiffs-only law firm, announced today a new alert concerning the Nuvaring contraceptive device. The firm reports on a new study published May 10, 2012 in the British Medical Journal (BMJ), that further reveals the risk of blood clots in women using the vaginal ring called the "NuvaRing." This information is critical in helping women to evaluate their risk of health issues when choosing contraception, and will also provide key evidence for those women who have been injured by the NuvaRing and are considering a NuvaRing lawsuit.
The NuvaRing birth control device was first approved by the FDA in 2001. In October 2011, the FDA released a drug safety study report indicating the NuvaRing was associated with a significantly higher risk of developing deep vein thrombosis (blood clots in the legs) and pulmonary embolism (blood clots in the lungs) than standard low-dose estrogen birth control pills. Now, according to new results published this month in the British Medical Journal, women using the vaginal ring are at a significantly higher risk for venous thrombosis (blood clots) compared to those taking earlier generation oral contraceptive birth control.
All hormonal contraceptions come with some risk of blood clots, which can lead to other complications like deep vein thrombosis and even life-threatening pulmonary embolism and stroke. Danish researchers, however, studied pregnant women ages 15-49 who were free of any prior thrombotic disease, between 2001 and 2010, and discovered that women who use vaginal rings like the NuvaRing for contraception have a 6.5 times increased risk of confirmed venous thrombosis compared with non-users of hormonal contraception.
The researchers further noted that “the vaginal ring conferred a 90% higher risk of venous thrombosis than did combined oral contraceptives containing levonorgestrel, bringing the risk to the same level as that of combined oral contraceptives with third and fourth generation progestogens”—such as Yaz and Yasmin. The researchers concluded that, "women are generally advised to use combined oral contraceptives with levonorgestrel or norgestimate, rather than to use transdermal patches or vaginal rings."
This NuvaRing study brings new information critical to women evaluating the use of their contraception. Chaffin Luhana LLP has a long and successful history of protecting the rights of women affected by the serious side effects of pharmaceutical drugs and medical devices. The firm experienced substantial growth in 2011, with partners Eric Chaffin and Roopal Luhana representing high-profile cases in federal and state courts across the country, and launching new online resource centers (including one for the NuvaRing) for clients and the public. The firm has a distinguished track record of success and is highly committed to each case.
If you or a loved one has suffered a serious injury related to the NuvaRing, contact a NuvaRing lawyer at Chaffin Luhana LLP for a free and confidential case review at 1-888-480-1123, or visit their website at http://www.chaffinluhana.com. A NuvaRing lawsuit may be able to help recover damages and ease the financial challenges of medical treatment.
Eric T. Chaffin, Esq.
CHAFFIN LUHANA LLP
600 Third Avenue, 12th Floor
New York, NY 10016
Toll Free Telephone: (888) 480-1123
Toll Free Fax: (888) 499-1123
Attorney Advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.